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Response Assessment Methods:
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Assisted Response Evaluation
abstract
Purpose To compare the effectiveness ofmetastatic tumor response evaluationwith computed tomography
using computer-assisted versus manual methods.
Materials and Methods In this institutional review board–approved, Health Insurance Portability and
Accountability Act–compliant retrospective study, 11 readers from 10 different institutions independently
categorized tumor response according to three different therapeutic response criteria by using paired
baseline and initial post-therapy computed tomography studies from 20 randomly selected patients with
metastatic renal cell carcinoma who were treated with sunitinib as part of a completed phase III multi-
institutional study. Images were evaluated with a manual tumor response evaluation method (standard of
care)andwith computer-assisted responseevaluation (CARE) that includedstepwiseguidance, interactive
error identification and correction methods, automated tumor metric extraction, calculations, response
categorization, and data and image archiving. A crossover design, patient randomization, and 2-week
washout periodwere used to reduce recall bias. Comparative effectivenessmetrics included error rate and
mean patient evaluation time.
Results The standard-of-caremethod, on average, was associatedwith one ormore errors in 30.5% (6.1 of
20) of patients, whereas CARE had a 0.0% (0.0 of 20) error rate (P < .001). The most common errors were
related to data transfer and arithmetic calculation. In patients with errors, themedian number of error types
was 1 (range, 1 to 3). Mean patient evaluation time with CARE was twice as fast as the standard-of-care
method (6.4 minutes v 13.1 minutes; P < .001).
Conclusion CARE reduced errors and time of evaluation, which indicated better overall effectiveness than
manual tumor response evaluation methods that are the current standard of care.
Clin Cancer Inform. © 2017 by American Society of Clinical Oncology
INTRODUCTION
In clinical trials and clinical practice, objective tumor
responseasevaluatedoncomputed tomography (CT)
images defines critical end points in patients with
metastatic disease who are treated with systemic
agents. Response Evaluation Criteria in Solid Tumors
(RECIST; version 1.1) is based on tumor length mea-
surements and is the most commonly used criteria
with which to longitudinally assess metastatic tumor
response for a wide variety of solidmalignancies.1,2 In
theeraof targetedtherapy,metastatic tumorshrinkage
has become less common or is delayed, which limits
the utility of RECIST version 1.1.3-7
Many targeted agents are classified as antiangio-
genic and cause tumor devascularization, which
leads to changes in tumor size, attenuation, and
morphology on CT images.8,9 Choi criteria, which
uses the percent change in tumor length and
attenuation to derive objective response, was ini-
tially successful in predicting tumor response and
survival in metastatic GI stromal tumors; however,
less consistent results were observed when Choi
criteria were applied to metastatic renal cell car-
cinoma (RCC) thatwas treatedwithantiangiogenic
targeted agents.8,9 MASS (Morphology, Attenua-
tion, Size, and Structure) criteria, which accounts
for objective changes in tumor length and atten-
uation and subjective development of tumor ne-
crosis, was subsequently developed and found to
be predictive of progression-free survival in pa-
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Computer-assisted detection, picture archiving
and communications systems, voice recognition
systems, and electronic medical records have
been designed to provide guidance, automate
tasks, reduce errors, and improve efficiency and
documentation in diagnostic imaging.10,11 De-
spite advances in tumor segmentation methods
and data management, the current standard of
care for assessing metastatic tumor response is to
manually apply tumor response criteria to derive
objective response and manually document the
findings.12-15 Thesemanualmethods are prone to
human errors in target lesion selection, target
lesion measurement, data transfer, data calcula-
tions, response categorization, and archiving of
data and annotated images.16-19 Furthermore,
these manual methods are potentially inefficient
andbecomeparticularly complexwhenevaluating
imagesbymultiple imagingcriteria,which isbecom-
ing more common in oncologic clinical trials.20,21
A computer-assisted response evaluation (CARE)
system has been developed to guide readers
through and to automate many of the steps in
tumor response assessment with the goal of re-
ducing errors and improving efficiency and doc-
umentation.22 In this study, we compared the
effectiveness of metastatic tumor response eval-
uation in patients with RCC using standard of care
versus a CARE method.
MATERIALS AND METHODS
Study Design
Informed consent was waived in this institutional
review board–approved, Health Insurance Porta-




An existing imaging data set from a multinational,
multi-institutional, prospective phase III trial of
adult patients with metastatic clear-cell RCC
who were treated with sunitinib or interferon alfa
was used.23 Three hundred seventy-five partici-
pants were included in the sunitinib arm. CT
images from this study were prospectively ar-
chived for central independent review. Patients
with unavailable baseline imaging or initial post-
therapy imaging (n = 61) and those with non-
digitized images (n = 39) were excluded, which
left 275 participants available for analysis. For our
study, images from 20 of 275 participants were
randomly selected for additional evaluation. A
power analysis for 11 readers with a cluster cor-
relation of 50% and expected patient-level error
percentage of 20% for standard of care and2% for
CARE yielded greater than 90% power to detect
differences between the two methods.
Image Acquisition
Baseline CT (CT0) and initial follow-up CT (CT1)
imaging of the chest, abdomen, and pelvis were
performed per routine institutional acquisition pa-
rameters with slice thickness at < 5 mm and
administration of intravenous iodinated contrast
unless contraindicated. Other CT acquisition and
contrast material injection parameters were not
specified, although CT manufacturer, number of
detector rows, and tube voltage were obtained
from images (Table 1). Images were deidentified
with a unique coded identifier that was applied to
each CT examination.
Readers
Eleven readers from 10 institutions participated in
this study. Readers had a median of 5 years of
post-training clinical experience (range, 2 to 23
years) and were practicing American Board of
Radiology–certified academic radiologistswith fel-
lowship training in body imaging. Readers were
providedwith awritten overview of RECIST version
1.1 and Choi andMASS criteria as well as relevant
literature concerning the various tumor response
criteria they were asked to review.1,9,24
Standard-of-Care Method
Readers were provided remote access to a stan-
dard image viewer (Philips iSite Enterprise, version
3.6.150.0 test environment; Philips, Andover,
MA). Readers used coded identification numbers
to locate and view CT0 and CT1 images. A Web-
based Qualtrics survey platform (Provo, UT) was
used to record data on target lesions and was
designed to mimic the use of electronic data
capturedevices that areused inmodernoncologic
clinical trials. Target lesion data entered by each
reader included the type of target lesion (primary
tumor, metastasis, or lymph node), target lesion
length (centimeters), andmeanattenuation (Houns-
field units), calculated percent change in length and
mean attenuation, presence or absence of marked
decreased attenuation or marked central necrosis
per MASS criteria, nontarget lesion response, and
objective response per RECIST version 1.1 andChoi
andMASScriteria. All readers reviewed a30-minute
instructional video that detailed the approach to the
standard-of-caremethod,useof theQualtrics survey
to record results, and a requirement to archive all
images that were annotated during review. Qualtrics
wasused to time the tumor response assessment for
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Table 1. Patient, Tumor, and Imaging Characteristics
Variable Whole Cohort (N = 275) Interobserver Cohort (n = 20)
Patient characteristic
Demographics
Median age (Q1, Q2), years 62 (53, 68) 64 (57.5, 71.5)
Male sex, No. (%) 205 (75) 16 (80)
MSKCC risk groups, No. (%)
Favorable risk 185 (67) 11 (55)
Intermediate risk 85 (31) 9 (45)
Poor risk 6 (2) 0 (0)
Survival, median (95% CI)
PFS, years 0.87 (0.35 to 1.45) 0.93 (0.63 to 1.58)
OS, years 2.23 (1.03 to 3.21) 2.59 (1.05 to 3.20)
Tumor characteristic
RCC pathologic type, No. (%)
Clear cell only 241 (88) 20 (100)
Mix with clear cell component 34 (12) 0 (0)
Target lesion locations, No. (%)
Lung 132 (48) 7 (35)
Mediastinal/hilar lymph nodes 107 (39) 6 (30)
Adrenal glands 64 (23) 1 (5)
Liver 49 (18) 3 (15)
Bones 42 (15) 4 (20)
Retroperitoneal lymph nodes 26 (9) 2 (10)
Other organ site 23 (8) 5 (25)
Other lymph nodes 4 (1) 0 (0)
Percent change in tumormetrics, median
(Q1, Q3)
Length, cm (N = 275) 210.44 (219.17, 21.15) 26.33 (214.55, 22.50)
Meanattenuation,HU(n=229contrast
enhanced)
232.06 (260.36, 0.06) 235.91 (259.68, 216.93)
Imaging characteristic
CT manufacturer, No. (%)
GE (Milwaukee, WI) 141 (51) 14 (70)
Siemens (Forchheim, Germany) 110 (40) 5 (25)
Philips (Amsterdam, the Netherlands) 22 (8) 1 (5)
Toshiba (Tokyo, Japan) 2 (1) 0 (0)
CT scanner detector rows, No. (%)
4 186 (68) 16 (80)
8 17 (6) 1 (5)
16 69 (25) 3 (15)
64 3 (1) 0 (0)
Peak kilovoltage, No. (%)
120 238 (87) 18 (90)
130 30 (11) 2 (10)
140 7 (2) 0 (0)
(continued on following page)
ascopubs.org/journal/cci JCO™ Clinical Cancer Informatics 3
Downloaded from ascopubs.org by UCL Library Services on February 25, 2019 from 128.041.035.059
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
each patient interpretation, from the loading of the
survey to export of the data.
CARE Method
A custom image-viewing and semiautomated ad-
vanced postprocessing software platform (eMASS)
was developed by A.D.S. and iteratively improved
upon in collaboration with software engineers from
ImageIQ.22 In brief, eMASS software was designed
to facilitate CARE of target lesions on baseline and
initial post-therapy imaging studies by providing
stepwise guidance of the required measurements
and observations, interactive error identification
and correction methods, and automated tumor
metric extraction, calculations, response categori-
zation, and data/image archiving. The software
identifiescommonerrors in tumor responseassess-
ment and implements corrective measures as de-
tailed in Table 2.16-19 Efficiency is improved via
automation of multiple steps, including the simul-
taneous extraction of bidimensional tumor length
and mean attenuation from a manual tumor seg-
mentation process in which free-form regions of
interest are drawn around the periphery of target
lesions by the reviewer. The software automatically
archives all data, annotates images, and instantly
generates a summary output display for the reader
to review (Fig 1).
All readers reviewed a 30-minute instructional
video that detailed the use of the CARE method.
A password-restricted encrypted data sharing
platform (Dropbox, San Francisco, CA) was used
to share eMASS software (version 1.0.24; eMASS
LLC, Birmingham, AL) and deidentified images.
Readers used their local personal computer run-
ning Windows 7 or higher (Microsoft, Redmond,
WA) to download the stand-alone software pack-
age. The software automatically timed the tumor
response assessment for each patient interpreta-
tion from the time of image loading until data
export. Exported data are automatically stored
in a comma-separated value format database.
Exported images are automatically stored inDigital
Imaging and Communications in Medicine and
Portable Network Graphics formats in the main
directory of the software.
Reading Sessions
All patients were evaluated once by using the
standard-of-care method and twice by using the
CARE method, with differences in how target
lesionswere identified. Acrossover design, patient
random assignment, and 2-week washout period
were used to reduce recall bias (Appendix, online
only). In brief, a total of 11 readers participated.
Two reader pools (1 and 2) and three reading
sessions (A, B, and C) were used. For reading
sessions A and B, readers were provided with
CT0 and CT1 images and independently picked
their own target lesions as they evaluated images.
Reading session C used the CARE method only,
was designed to eliminate interobserver variability
as a result of target lesion selection, and used a set
Table 1. Patient, Tumor, and Imaging Characteristics (continued)
Variable Whole Cohort (N = 275) Interobserver Cohort (n = 20)
Time of CT scans relative to start of
therapy, median (Q1, Q3)
Baseline (CT0), days 211 (215, 27) 28.5 (212.5, 26.5)
Initial post-therapy (CT1), days 28 (26, 29) 27.5 (27, 29.5)
Contrast enhancement, No. (%)
CT0 and CT1 contrast enhanced 229 (83) 18 (90)
CT0 and CT1 nonenhanced 21 (8) 2 (10)
CT0 nonenhanced, CT1 contrast
enhanced
10 (4) 0 (0)
CT0 contrast enhanced, CT1
nonenhanced
15 (5) 0 (0)
Phase of IV contrast (n = 229 contrast
enhanced), No. (%)
Same contrast phase for CT0 and CT1 220 (96) 20 (100)
CT0 contrast phase earlier than CT1 5 (2) 0 (0)
CT0 contrast phase later than CT1 4 (2) 0 (0)
Abbreviations: CT, computed tomography; CT0, baseline CT; CT1, initial post-therapy CT; HU, Hounsfield units; IV, intravenous; MSKCC,
Memorial Sloan Kettering Cancer Center; OS, overall survival; PFS, progression-free survival; Q, quartile; RCC, renal cell carcinoma.
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Table 2. Computer-Assisted Solutions to Common Sources of Error in Tumor Response Assessment




Error in target lesion selection per RECIST
version 1.1
Selection of more than five total target
lesions
Assign all target lesions a number and prohibit
the selection of more than five target lesions.
Selection of more than two target lesions
per organ system
Require assignment of all target lesions to an
organ system by using a dropdown list,
provide user with a warning when selection of
more than two target lesions per organ system
is made, and prevent additional analysis until
error is corrected.
Selection of ametastasismeasuring,1.0
cm in long axis
Require labeling of all target lesions as primary
mass, metastasis, or lymph node. Notify
reader of an error if primary mass or
metastasis measures, 1.0 cm in long axis or
if lymph node measures , 1.5 cm in short
axis, andpreventadditional analysisuntil error
is corrected.
Selection of a lymph node measuring ,
1.5 cm in short axis
Error in target lesion measurement
Metastasis measured in short axis Eliminate manual data transfer. The user places
a free-form ROI around the peripheral margin
of the tumor on the axial image where the
target lesion is the largest (per RECIST version
1.1 guidelines). The long axis length is
automatically derived and archived in
a database for all target lesions labeled as
a primary mass or metastasis. The short axis
length is automatically derived and archived
in a database for all target lesions labeled as
lymph nodes.
Lymph node measured in long axis
Error in data transfer
. 0.5 cm in length between annotated
image and database
Eliminate manual data transfer by automatically
extracting andarchiving all tumormetric data.
. 5 HU difference between annotated
image and database
Error in application of MDA* per MASS
criteria
Failure to identifyMDA despite decreased
attenuation > 40 HU
Eliminate manual detection of MDA by
automatically calculating theabsolutechange
in attenuation of all target lesions and
automatically recording MDA as present if
a target lesion decreases by > 40 HU. Note
that the user is required to enter information
on the presence or absence of intravenous
contrast before selecting any target lesions,
and MDA is not assessed if either study is not
contrast enhanced.
MDA applied to a lung target lesion Prevent assessment for MDA for target lesions
with organ system labeled as lung.
Error in calculation on the basis of tumor
measurements
Incorrect calculation of percent change in
size
Eliminate manual calculations by automatically
calculating percent change in size,
attenuation, and other tumor metrics.Incorrect calculation of percent change in
tumor attenuation
(continued on following page)
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arrangement of target lesion images that were
provided to all readers.
For reading session A, reader pool 1 evaluated
participants 1 to 10 by using the standard-of-care
method, followed by participants 11 to 20 by using
the CARE method. Reader pool 2 evaluated par-
ticipants 11 to 20 by using the standard-of-care
method, followed by participants 1 to 10 by using
the CARE method.
To reduce recall bias, readers waited at least
14 days before beginning session B. For reading
session B, reader pool 1 evaluated participants 1
to 10 in a randomized order by using the CARE
method, followed by participants 11 to 20 in a
randomized order by using the standard-of-care
method. Reader pool 2 evaluated participants 11
to 20 in a randomized order by using the CARE
method, followed by participants 1 to 10 in a
randomized order by using the standard-of-care
method (Appendix Fig A1, online only).
Reading session C was designed to eliminate in-
terobserver variability as a result of target lesion
selection. Target lesions were identified by A.D.S.,
and singleDigital Imaging andCommunications in
Medicine format images with each target lesion
from CT0 and CT1 were provided to readers. All
readers used an imaging atlas—digital slides that
contained pictures of each target lesion with
an arrow pointing to the target—and evaluated
participants 1 to 20 by using the CARE method.
For the purposes of this article, CARE1 indicates
that the readers picked their own target lesions,
and CARE2 indicates that the target lesions were
preselected for the readers.
Tumor Response Error Rate and Type Analysis
Two imaging research fellows—E.F. and R.S.—
independently used the output data from the
Qualtrics platform and the output file from the
CARE method, along with the archived annotated
images, to manually identify and record the pres-
ence or absence of all common tumor response
error types identified in Table 2. Only a single error
event per patient was recorded for each error type,
even ifmultiple errors of the same type occurred in
thesamepatient.A third reviewer—B.C.A.,a reader
from the study—evaluated all potential errors that
were identified by E.F. and R.S. In the case of any
discrepancy between the three reviewers, a panel
that consisted of five readers from the study eval-
uated the potential errors by consensus.
Post-study Survey
Apost-studyQualtrics survey thatwas unrelated to
the data capture mechanism and designed to
assess reader opinion about the CARE method
was completed by all readers (N = 11) before an
analysis of the study data and results.
Table 2. Computer-Assisted Solutions to Common Sources of Error in Tumor Response Assessment (continued)




Error in objective response categorization on
the basis of calculations
RECIST version 1.1 categorization error Eliminate manual objective response
categorization. During the computer-assisted
tumor responseassessment process, theuser
is required to enter information on nontarget
lesion response, presence or absence of one
or more new metastases, and presence or
absence of marked central necrosis (for
MASS criteria). The software automatically
calculates the percent change in all tumor
metrics and combines this information with
the above to automatically derive objective
response per RECIST version 1.1, Choi
criteria, MASS criteria, and a number of other
tumor response criteria.
Choi criteria categorization error
MASS criteria categorization error
Error in image archiving
Failure to store annotated images Eliminate the need for manual image storage by
automatically storing annotated images.
Abbreviations: HU,Hounsfield units; MASS,Morphology, Attenuation, Size, and Structure;MDA,marked decreased attenuation; ROI, region
of interest.
*MDA is defined as. 40-HU decrease in themean attenuation of a target lesions compared with baseline. According toMASS criteria, MDA
should not be applied to lung target lesions.
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Statistical Analysis
Patient, imaging, and measurement characteris-
tics were summarized asmedian and interquartile
range for continuous variables and count (per-
centage) for categorical variables for both the 275
patientswho satisfied the inclusion criteria and the
subset of 20 patients used in primary results.
Side-by-side boxplots were constructed to com-
pare interpretation timebetween standard-of-care
and CARE1 methods. Scatter plots were con-
structed to visualize thedistributionsof thepercent
change in tumor length and mean attenuation in
eachpatientbyusing thestandard-of-care,CARE1,
and CARE2 methods.
Average percent of errors per patient was calcu-
lated by using themarginal effect from amultilevel
mixedmodel, clustered by reader. Multiplying this
by 20—the number of patients read by each
reader—yields the expected number of errors
per reader. Comparisons between the standard-
of-care and CARE1methods were drawn from the
fixedeffectof thismodel.Agreementacross readers
was assessed via intraclass correlation coefficients
(ICCs) computed from two-way random effects
models. ICC values were characterized as poor
(0.00 to, 0.25), moderate (0.25 to, 0.50), good
(0.50 to, 0.75), and very good (0.75 to 1.00). All
analyseswereperformedwithSTATA(version14.1;
STATA, College Station, TX; Computing Resource
Center, Santa Monica, CA).
RESULTS
Patient, Tumor, and Imaging Characteristics
The study cohort (n = 20) was randomly selected
from the full cohort (N = 275) and had similar
baseline characteristics (Table 1).
Tumor Response Error Rate and Type
The standard-of-caremethodwas associated with
errors types in all categories, including target
lesion selection, target lesion measurement, data
transfer, application of MASS criteria, tumor met-
ric calculations, objective response categoriza-
tion, and annotated image archiving (Table 3).
The most common errors were related to data
transfer and calculation.
The standard-of-care method, on average, was
associatedwithoneormoreerrors in30.5%(6.1of
A
Fig 1. (A) Screenshot of
eMASS software viewer and
(B) summary output
display. (A) The software




(CT0; on left) and initial
post-therapy CT images
(CT1; right) and make
measurements. The target
lesion in the peritoneum
was selected by using
a free-form region of
interest, and the tumor
metrics are automatically
derived and displayed. The
red color highlights the
vascular tumor burden
(VTB; enhancing tumor),





evaluation by guiding the
user through the tumor
assessment process. As the
software identifies errors in
tumor response
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20) of patients, whereas the CARE method had a
0.0% (0.0 of 20) error rate (P , .001). The error
rate for the standard-of-care method was similar
between reading sessions 1 and 2 (Appendix
Table A1). The median error rate for 11 readers
who interpreted 20 cases using the standard-of-
care method was 25% (range, 15% to 55%). In
patients with errors, the median number of error
types was 1 (range, 1 to 3). When considering total
errors per response criteria using the standard-of-
care method, errors were more common when
applyingChoi criteria (24.5% [4.9 of 20]) andMASS
criteria (23.0% [4.6 of 20]) compared with RECIST
version 1.1 (11.0% [2.2 of 20]; P, .001 for both).
Interpretation Time
Mean patient interpretation time was twice as
fast when using the CARE compared with the
standard-of-care method: 6.4 minutes (95% CI,
6.11 to 6.66) v 13.1 minutes (95% CI, 12.5 to
13.7), respectively (P , .001; Appendix Fig A2,
online only).
Interobserver Agreement
Interobserver agreement results are summarized
in Table 4. There was very good interobserver
agreement for measuring length and mean atten-
uation when readers used the CARE method to
evaluate preselected target lesions (CARE2 range
of ICC, 0.95 to 0.98), which resulted in a higher
level of agreement than when readers chose their
own target lesions (standard-of-care range of ICC,
0.59 to 0.89; CARE1 range of ICC, 0.69 to 0.88).
Similarly, improved interobserver agreement for
measuring the percent change in length was ob-
served when readers used the CARE method to
evaluate preselected target lesions (CARE2 ICC,
0.89), which resulted in a higher level of agree-
ment than when readers chose their own tar-
get lesions (standard-of-care ICC, 0.79; CARE1
ICC, 0.59); however, when using either reader-
selected or preselected target lesions, there was
poor agreement for the percent change in mean
attenuation (range of ICC, 0.00 to 0.06), which is
used in Choi criteria. Distributions of the percent
change in tumor length and mean attenuation for
each patient according to tumor response evalua-
tion method are depicted graphically in Fig 2.
Post-study Survey
Thepost-studysurvey indicatedthat100%ofreaders
(11 of 11) strongly preferred the CARE method and


















Length = 17.4 cm
Mean Atten = 64 HU
Area = 36.6 cm2
VTB Area = 22.7 cm2
Necrosis Area = 13.6 cm2
Change
%Length = –11.0%
%Mean Atten = –67.0%
%Area = –14.0%
%VTB Area = –61.0%
%Necrosis Area = 60.0%
Nontargets = Non-CR/Non-PD
New Metastasis = No
Response
RECIST = SD
10% Criteria = PR
Choi = PR




Length = 15.5 cm
Mean Atten = 21 HU
Area = 31.6 cm2
VTB Area = 8.8 cm2
Necrosis Area = 21.8 cm2
B
Fig 1. (Continued).
assessment, a dialogue box
in thesidepanel indicates the
required corrective action
and theusermust correct the
error before moving to the
next task. The software also
automates a number of




output (B) is automatically
generated and displayed in
, 1 second. Target lesions
are displayed in scaled
vertical columns to visually
display the tumor burden.
Tumor metrics and objective
responsepermultiple criteria
are automatically derived
and provided in the output
display. Atten, attenuation;
CR, complete response; FR,
favorable response; HU,






partial response; SD, stable
disease.
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Table 3. Errors in Tumor Response Assessment According to Evaluation Method
Errors in Tumor Response Assessment Standard of Care CARE P
Error in target lesion selection per RECIST
version 1.1
Selection of more than five total target
lesions
0.0% (0.0/20) 0.0% (0.0/20) —
Selection of more than two target lesions
per organ system
1.5% (0.3/20) 0.0% (0.0/20) .074
Selection of ametastasismeasuring,1.0
cm in long axis
0.0% (0.0/20) 0.0% (0.0/20) —
Selection of a lymph node measuring
, 1.5 cm in short axis
2.0% (0.4/20) 0.0% (0.0/20) .043
Error in orientation of target lesion
measurement
Metastasis measured in short axis 0.0% (0.0/20) 0.0% (0.0/20) —
Lymph node measured in long axis 2.0% (0.4/20) 0.0% (0.0/20) .035
Error in data transfer
. 0.5 cm in length between annotated
image and database
1.5% (0.3/20) 0.0% (0.0/20) .079
. 5 HU difference between annotated
image and database
6.5% (1.3/20) 0.0% (0.0/20) , .001
Error in application of MDA* per MASS
criteria
Failure to identifyMDA despite decreased
attenuation > 40 HU
3.0% (0.6/20) 0.0% (0.0/20) .007
MDA applied to a lung target lesion 2.5% (0.5/20) 0.0% (0.0/20) .013
Error in calculation on the basis of tumor
measurements
Incorrect calculation of percent change in
size
2.0% (0.4/20) 0.0% (0.0/20) .043
Incorrect calculation of percent change in
tumor attenuation
6.0% (1.2/20) 0.0% (0.0/20) , .001
Error in objective response categorization on
the basis of calculations
RECIST version 1.1 categorization error 1.0% (0.2/20) 0.0% (0.0/20) .155
Choi criteria categorization error 3.0% (0.6/20) 0.0% (0.0/20) .007
MASS criteria categorization error 5.0% (1.0/20) 0.0% (0.0/20) .001
Error in image archiving
Failure to store annotated images 2.5% (0.5/20) 0.0% (0.0/20) .012
Total errors per response criteria
RECIST version 1.1 errors 11.0% (2.2/20) 0.0% (0.0/20) , .001
Choi criteria errors 24.5% (4.9/20) 0.0% (0.0/20) , .001
MASS criteria errors 23.0% (4.6/20) 0.0% (0.0/20) , .001
Total errors for complete assessment by
three response criteria
30.5% (6.1/20) 0.0% (0.0/20) , .001
NOTE. Summary statistics are presented as the average percentage of errors per patient (average number of errors per reader/average
number of patient assessments per reader), across 11 independent readers. Only a single error event per patient was recorded for each error
type, even if multiple errors of the same type occurred in the same patient.
Abbreviations: CARE, computer-assisted response evaluation; HU, Hounsfield units; MASS, Morphology, Attenuation, Size, and Structure;
MDA, marked decreased attenuation.
*MDA is defined as. 40-HU decrease in themean attenuation of a target lesions compared with baseline. According toMASS criteria, MDA
should not be applied to lung target lesions.
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standard-of-care method. Most readers (73%; eight
of 11) indicated that CARE would improve overall
productivity in the clinical setting, with 18% (two of
11) undecided and 9% (one of 11) indicating that
productivitywouldnotbeimproved.Additionalsurvey
results are provided in the Appendix.
DISCUSSION
The current standard-of-care for assessing meta-
static tumor response is to manually apply tumor
response criteria to derive the objective response
and manually document the results. In our study,
the standard-of-care method was associated
with a high error rate, despite the use of expert
readers and training before reading sessions.
Similar findings have been reported by using
RECIST version 1.1 in clinical practice, but have
not been confirmed in a multi-institutional study.17
Past efforts to reduce readererrorsand interobserver
variability in tumor response assessment have in-
cluded reader educational training and the use of
central independent image review in oncologic clin-
ical trials, which have mildly reduced errors and
improved interobserver variability.17,25-27
In our study, the use of the CARE method with
step-wise guidance and interactive error identifi-
cation and correction methods eliminated reader
errors and achieved good to very good interob-
server agreement. This is a clinically important
finding, as errors in tumor response evaluation
may adversely impact treatment decisions.
CARE was used to automate tumor metric ex-
traction, calculations, response categorization,
and data and image archiving, which resulted
in markedly improved efficiency as the mean
interpretation timewas cut in half comparedwith
the standard-of-care method.
Weobservedhigh inter-readeragreement formea-
suring multiple tumor metrics by using the CARE
method, despite the use of 11 readers from 10
different institutions with varying experience and
practice patterns with less than 1 hour of training
with the CARE method. Two observations are
noteworthy. First, interobserver agreement using
either the standard-of-care or CARE methods for
measuring mean attenuation was good, but was
dismal for percent change in mean tumor atten-
uation, even when all readers measured the same
preselected target lesions. This implies that the
mathematical conversion to percent change in
mean attenuation is responsible for the poor in-
terobserver agreement, which is likely related to
the fact that zeromeanattenuation is an arbitrary—
not absolute—definition and is not comparable to a
length measurement of zero, which is an absolute
value that indicates that no tumor is present. These
findings suggest that the percent change in mean
attenuationmaynot be reproducible inChoi criteria
and modified Choi criteria. Second, interobserver
agreement for measuring length with the CARE
method was higher when target lesions were pre-
selected for readers than when readers selected
their own target lesions, which indicated that target
lesion selection is a major contributor to interob-
server variability.
This study had several limitations. First, the study
was retrospective in design, although CT images
were a representative sample from a landmark
multinational, multi-institutional, phase III prospective
study and the standard-of-care tumor response
Table 4. Interobserver Agreement According to Response Evaluation Method
Descriptor Standard of Care CARE 1 CARE 2
Length
Sum at CT0, cm 0.89 (0.81 to 0.94) 0.88 (0.80 to 0.94) 0.98 (0.97 to 0.99)
Sum at CT1, cm 0.89 (0.81 to 0.94) 0.88 (0.80 to 0.94) 0.98 (0.97 to 0.99)
Change, cm 0.75 (0.62 to 0.87) 0.60 (0.44 to 0.77) 0.90 (0.82 to 0.96)
Percent change 0.79 (0.67 to 0.89) 0.59 (0.43 to 0.76) 0.89 (0.81 to 0.95)
Attenuation
Mean at CT0, HU 0.79 (0.70 to 0.90) 0.69 (0.53 to 0.84) 0.95 (0.90 to 0.98)
Mean at CT1, HU 0.59 (0.45 to 0.78) 0.80 (0.69 to 0.90) 0.97 (0.95 to 0.99)
Change, HU 0.47 (0.33 to 0.69) 0.38 (0.23 to 0.61) 0.85 (0.74 to 0.94)
Percent change 0.00 (20.06 to 0.03) 0.06 (0.00 to 0.22) 0.00 (20.04 to 0.14)
NOTE.Dataarepresentedas intraclass correlationcoefficient (95%CI). For the standard-of-careandCARE1methods, readers independently
picked all target lesions. For the CARE 2method, target lesions were provided to all readers before evaluation. A comparison of CARE1 versus
CARE 2 methods allows for an assessment of the role of target lesion selection in tumor response assessment.
Abbreviations: CARE, computer-assisted response evaluation; CT0, baseline computed tomography exam; CT1, initial follow-up computed
tomography exam; HU, Hounsfield units.
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evaluation process was similar to methods that
are used in prospective multi-institutional stud-
ies. Second, the high per-patient error rates in
our study likely underestimate true error rates as
readers only evaluated two imaging time points
and did not perform longitudinal tumor assess-
ments that are used in clinical trials and clinical
practice and only one error type per patient was
counted, despite the possibility of compoun-
ded errors—for example, a target lesion selection
error that leads tomeasurement, calculation, and
response categorization errors at the current time
point or later time points. Third, the same set of
patient images was evaluated twice by readers so
that a direct comparison of two tumor response
assessment methods could be made, potentially
leading to recall bias. Efforts to reduce recall
bias included the crossover study design, patient
randomization and deidentification, and a 2-week
washoutperiodbetween reading sessions. Fourth,
the study was not designed or powered to as-
sess longitudinal differences in objective tumor
response reclassification or changes in clinical
management associated with use of the CARE
method. Fifth, our study focused only on tumor
assessments using CT images; however, the
basic rule-setting structure is amenable to other
imaging modalities.
In conclusion, the CARE method significantly
reduces errors and time of evaluation while
maintaining high interobserver agreement,
which indicates better overall effectiveness than
manual tumor response evaluation methods
that are the current standard of care. As meta-
































Standard of care (ICC, 0.00)
CARE1 (ICC, 0.06)
CARE2 (ICC, 0.00)
Fig 2. Scatter plots depicting the distributions of percent change in tumor length and mean attenuation for each patient according to tumor response
evaluation method. Readers (N = 11) picked the target lesions for the standard-of-care and computer-assisted response evaluation (CARE1) methods, but
images of preselected target lesions were used for CARE2. Interobserver agreement was good to very good for measuring percent change in tumor length.
Patients 1 and20 had nonenhanced computed tomography images, somean attenuationwas notmeasured in these patients. Interobserver agreement was
poor for measuring percent change in mean attenuation by any of the methods tested. To facilitate a direct comparison, y-axis scales for each graph were
restricted to the same range (2100% to +100%); however, for percent change in mean attenuation, there were 136 values outside of this range, with 13
having . 1000% change and three having . 5,000% change. ICC, intraclass correlation coefficient.
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end points in oncologic patient care, methods
that reduce errors, reduce time of evaluation,
and improve documentation while maintaining
high interobserver agreement could lead to
needed advancements in clinical trials and clin-
ical care.
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APPENDIX Reading Sessions
All patients were evaluated once by using the standard-of-care method and twice by using the computer-assisted response
evaluation (CARE) method, with differences in how target lesions were identified. A crossover design, patient random
assignment, and 2-week washout period were used to reduce recall bias. In brief, a total of 11 readers participated. Two
reader pools (1 and 2) and three reading sessions (A, B, and C) were used. For reading sessions A and B, readers were
provided with images from baseline computed tomography exam and initial follow-up computed tomography exam, and
readers independently picked their own target lesions as they evaluated the images. Reading session C used the CARE
method only, was designed to eliminate interobserver variability as a result of target lesion selection, and used a set
arrangement of target lesion images that were provided to all readers.
For reading session A, reader pool 1 evaluated participants 1 to 10 by using the standard-of-care method followed by
participants 11 to 20byusing theCAREmethod.Reader pool 2 evaluatedparticipants 11 to20byusing the standard-of-care
method followed by participants 1 to 10 by using the CARE method.
To reduce recall bias, readers waited at least 14 days before beginning session B. For reading session B, reader pool 1
evaluated participants 1 to 10 in a randomized order by using the CARE method followed by participants 11 to 20 in a
randomized order by using the standard-of-care method. Reader pool 2 evaluated participants 11 to 20 in a randomized
orderbyusing theCAREmethod followedbyparticipants1 to10 ina randomizedorderbyusing the standard-of-caremethod
(Fig. A1).
Reading sessionCwasdesigned to eliminate interobserver variability as a result of target lesion selection. Target lesionswere
identified by A.D.S. and single Digital Imaging and Communications in Medicine format images with each target lesion from
baselinecomputed tomographyexamand initial follow-upcomputed tomographyexamwereprovided to readers.All readers
used an imaging atlas—digital slides that contained pictures of each target lesion with an arrow pointing to the target—and
evaluated participants 1 to 20 by using the CAREmethod. For the purposes of this article, CARE1 indicates that the readers
picked their own target lesions, and CARE2 indicates that the target lesions were preselected for the readers.
Post-study Survey
The post-study survey indicated that 100%of readers (11 of 11) strongly preferred the CAREmethod and found CARE to be
much easier to use than the standard-of-care method. Most readers (73%; eight of 11) indicated that CARE would improve
overall productivity in the clinical setting, with 18% (two of 11) undecided and 9% (one of 11) indicating that productivity
would not be improved. Most readers (82%; nine of 11) indicated that CARE would improve accuracy compared with the
standard-of-care method, with 9% (one of 11) undecided, and 9% (one of 11) indicating that CARE would not improve
accuracy. Most readers (82%; nine of 11) indicated that they would be very likely to use CARE in the future, with 9% (one of
11) indicating that they were somewhat likely and 9% (one of 11) undecided.
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Reader Pools Session A
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Table A1. Errors in Tumor Response Assessment According to Reading Session
Errors in Tumor Response Assessment
Standard of Care CARE
Session 1 Session 2 P Session 1 Session 2 P
Error in target lesion selection per RECIST
version 1.1
Selection of more than five total target
lesions
0.0% (0.0/20) 0.0% (0.0/20) — 0.0% (0.0/20) 0.0% (0.0/20) —
Selection of more than two target lesions
per organ system
2.5% (0.5/20) 0.0% (0.0/20) .064 0.0% (0.0/20) 0.0% (0.0/20) —
Selection of ametastasismeasuring,1.0
cm in long axis
0.0% (0.0/20) 0.0% (0.0/20) — 0.0% (0.0/20) 0.0% (0.0/20) —
Selection of a lymph node measuring
, 1.5 cm in short axis
1.0% (0.2/20) 2.5% (0.5/20) .312 0.0% (0.0/20) 0.0% (0.0/20) —
Error in orientation of target lesion
measurement
Metastasis measured in short axis 0.0% (0.0/20) 0.0% (0.0/20) — 0.0% (0.0/20) 0.0% (0.0/20) —
Lymph node measured in long axis 0.0% (0.0/20) 3.0% (0.6/20) .027 0.0% (0.0/20) 0.0% (0.0/20) —
Error in data transfer
. 0.5 cm in length between annotated
image and database
0.0% (0.0/20) 2.5% (0.5/20) .075 0.0% (0.0/20) 0.0% (0.0/20) —
. 5 HU difference between annotated
image and database
6.0% (1.2/20) 7.5% (1.5/20) .786 0.0% (0.0/20) 0.0% (0.0/20) —
Error in application of MDA* per MASS
criteria
Failure to identifyMDA despite decreased
attenuation > 40 HU
3.0% (0.6/20) 2.5% (0.5/20) .700 0.0% (0.0/20) 0.0% (0.0/20) —
MDA applied to a lung target lesion 2.0% (0.4/20) 3.0% (0.6/20) .407 0.0% (0.0/20) 0.0% (0.0/20) —
Error in calculation on the basis of tumor
measurements
Incorrect calculation of percent change in
size
3.0% (0.6/20) 0.0% (0.0/20) .041 0.0% (0.0/20) 0.0% (0.0/20) —
Incorrect calculation of percent change in
tumor attenuation
7.5% (1.5/20) 5.5% (1.1/20) .579 0.0% (0.0/20) 0.0% (0.0/20) —
Error in objective response categorization on
the basis of calculations
RECIST version 1.1 categorization error 2.0% (0.4/20) 0.0% (0.0/20) .153 0.0% (0.0/20) 0.0% (0.0/20) —
Choi criteria categorization error 3.0% (0.6/20) 2.5% (0.5/20) .700 0.0% (0.0/20) 0.0% (0.0/20) —
MASS criteria categorization error 4.0% (0.8/20) 5.5% (1.1/20) .757 0.0% (0.0/20) 0.0% (0.0/20) —
Error in image archiving
Failure to store annotated images 4.0% (0.8/20) 1.0% (0.2/20) .087 0.0% (0.0/20) 0.0% (0.0/20) —
Total errors per response criteria
RECIST version 1.1 errors 12.5% (2.5/20) 10.0% (2.0/20) .509 0.0% (0.0/20) 0.0% (0.0/20) —
Choi criteria errors 26.5% (5.3/20) 22.5% (4.5/20) .527 0.0% (0.0/20) 0.0% (0.0/20) —
MASS criteria errors 23.0% (4.6/20) 23.0% (4.6/20) . .999 0.0% (0.0/20) 0.0% (0.0/20) —
Total errors for complete assessment by
three response criteria
32.5% (6.5/20) 29.0% (5.8/20) .555 0.0% (0.0/20) 0.0% (0.0/20) —
Abbreviations: CARE, computer-assisted response evaluation; HU, Hounsfield units; MDA, marked decreased attenuation; MASS criteria, Morphology, Attenuation, Size, and
Structure criteria.
*MDA is defined as. 40 HU decrease in the mean attenuation of a target lesions compared with baseline. According to MASS criteria, MDA should not be applied to lung target
lesions.
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